Clinical trials: Pediatric Central Nervous System Tumors
Brain Tumor, Pediatric
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors
In this prospective, open, single-armed, multicenter, phase II study for application of 5-ALA in children and adolescents with brain tumors 80 patients will be investigated.
- Trial name
- NCT04738162
- Testing
- 5-Aminolevulinic Acid Hydrochloride, Oral
- Where
- 7 sites in Germany, Netherlands
- Volunteers
- 78 people
- Sponsor
- Universität Münster
Medulloblastoma, Central Nervous System Tumor, Pediatric
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum.
- Conditions
- Medulloblastoma, Central Nervous System Tumor, Pediatric, Ependymoma, Germ Cell Tumor
- Trial name
- GRIPP (NCT05672043)
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Beijing Tiantan Hospital
Brain Tumor, Microbiota
MICRO-BRAIN 2024: Study on Pediatric Brain Tumors
In recent years, there has been growing interest in the human gut microbiota, whose health is characterised by high microbial diversity.
- Trial name
- NCT07417085
- Testing
- Biological samples, Fecal samples
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Meyer Children's Hospital IRCCS
Central Nervous System Cancer
CNS Qualitative Interview
Explore factors involved in decision making for patients with new or recurrent CNS tumors and their families surrounding treatment planning and clinical trial enrollment.
- Trial name
- NCT05219149
- Testing
- Qualitative Interviews
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Colorado, Denver
Dystonia
Childhood Hypertonia of Central Origin: A Trial of Anticholinergic Treatment Effects
This study is an open-label trial of trihexyphenidyl in children with upper extremity dystonia due to cerebral palsy. It is hypothesized that trihexyphenidyl in doses up to 0.75mg/kg/day would be well-tolerated and show…
- Trial name
- NCT00122044
- Testing
- trihexyphenidyl
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Central Nervous System Tumor, Brain Tumor
Medical Marijuana in the Pediatric Central Nervous System Tumor Population
This study proposes to do a prospective observational cohort study evaluating the quality of life (QOL) of children with Central Nervous System (CNS) tumors and their families who choose to self-medicate with marijuana-derived…
- Conditions
- Central Nervous System Tumor, Brain Tumor, Spinal Tumor
- Trial name
- NCT03052738
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH
Sarcoma, Neuroblastoma
A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors
Background: Pazopanib, a drug that inhibits the growth of new blood vessels in tumors, was recently approved by the Food and Drug Administration to treat advanced kidney cancer in adults.
- Conditions
- Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma
- Trial name
- NCT01130623
- Testing
- Pazopanib (GW786034)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with SC-CAR4BRAIN, an autologous CD4+ and CD8+ T cells lentivirally transduced to express to express combinations of B7-H3, EGFR806, HER2, and…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, Recurrent CNS Tumor, Adult, Recurrent, CNS Tumor, Childhood
- Trial name
- NCT05768880
- Testing
- SC-CAR4BRAIN
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Seattle Children's Hospital
Brain Tumor, Pediatric, Brainstem Glioma, Brain Tumor, Pediatric, Recurrent
Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca
This Protocol is a pilot, clinical interventional study to selected patients between five and fourteen years of both sexes, carriers of the diagnosis of glioma brain stem and high grade recurrent in the central nervous system…
- Trial name
- NCT03250520
- Testing
- Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Hospital Infantil de Mexico Federico Gomez
Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
This is a Phase 1/2, multicenter, open-label trial of avapritinib in participants 2 to < 18 years of age with advanced relapsed/refractory (R/R) solid tumors, including central nervous system (CNS) tumors, that harbor a PDGFRA…
- Conditions
- Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm, CNS Tumor
- Trial name
- NCT04773782
- Testing
- avapritinib
- Where
- 26 sites in United States, Australia and 7 more
- Volunteers
- 29 people
- Sponsor
- Blueprint Medicines Corporation
Brain and Central Nervous System Tumors
PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors
RATIONALE: PTC299 may stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and the best dose of PTC299 in treating young patients with recurrent or…
- Trial name
- NCT01158300
- Testing
- VEGF inhibitor PTC299
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Pediatric Brain Tumor Consortium
Teratoid Tumor, Atypical, Choroid Plexus Neoplasms
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors.
- Conditions
- Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01975116
- Testing
- azurin-derived cell-penetrating peptide p28
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pediatric Brain Tumor Consortium
Central Nervous System Tumor
Longitudinal Study of Biomarkers
Biomarkers are small molecules that can be detected in the body fluids of patients; they often correlate with the presence of a cancer. MicroRNAs and proteins are small molecules which have recently been discovered in cells.
- Trial name
- NCT01595126
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Solid Tumors Harboring NTRK Fusion
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
The study is being done to test the safety of a cancer drug called larotrectinib in children. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3).
- Trial name
- SCOUT (NCT02637687)
- Testing
- Larotrectinib (Vitrakvi, BAY2757556)
- Where
- 45 sites in United States, Australia and 19 more
- Volunteers
- 154 people
- Sponsor
- Bayer
Glioblastoma Multiforme, Glioblastoma
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
This is a phase I study to assess the safety and feasibility of IL-8 receptor modified patient-derived activated CD70 CAR T cell therapy in CD70+ adult glioblastoma
- Trial name
- IMPACT (NCT05353530)
- Testing
- Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Florida
Brain Tumor, Malignant Neoplasm of Fourth Ventricle of Brain
Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study
The goal of this clinical research study is to learn if it is safe to receive methotrexate through the fourth ventricle of the brain in patients with brain tumors.
- Trial name
- NCT01737671
- Testing
- Ommaya Reservoir, Methotrexate, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Pediatric Brain Stem Glioma
Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children
This Trial offers a reduction in patient burden, which is especially preferable in children with a poor compliance and poor performance status.
- Trial name
- NCT01878266
- Testing
- Hypofractionated Arm (1), Hypofractionated Arm (2), Conventional Arm (3)
- Where
- Egypt
- Volunteers
- 119 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Headache, Urinary Incontinence
Pediatric Patient Experience on a Diagnostic Path
The trial will determine the impact of an information- and education-focused interventions on the anxiety levels, and patients' experiences as well as satisfaction of patients aged 10-14 and their caregivers during the MR…
- Conditions
- Headache, Urinary Incontinence, Growth Deficiency, Visual Impairment
- Trial name
- NCT05199363
- Testing
- Information leaflet, Educational movie, Demonstration
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Children's Memorial Health Institute, Poland
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)